12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Autologous dermal sheath cup cells: Phase I/II data

Interim data from the double-blind, placebo-controlled, Georgian Phase I/II TS001-2009 trial in 19 patients showed that injections of autologous DSCCs were well tolerated with no serious adverse events reported at 6 months. RepliCel said only a few mild cases of scalp irritation were observed. In 16 evaluable...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >